Jurj Ancuta, Fontana Beatrice, Varani Gabriele, Calin George A
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy.
Trends Cancer. 2024 Sep;10(9):809-824. doi: 10.1016/j.trecan.2024.06.006. Epub 2024 Aug 5.
Noncoding RNAs, especially miRNAs, play a pivotal role in cancer initiation and metastasis, underscoring their susceptibility to precise modulation via small molecule inhibitors. This review examines the innovative strategy of targeting oncogenic miRNAs with small drug-like molecules, an approach that can reshape the cancer treatment landscape. We review the current understanding of the multifaceted roles of miRNAs in oncogenesis, highlighting emerging therapeutic paradigms that have the potential to expand cancer treatment options. As research on small molecule inhibitors of miRNA is still in its early stages, ongoing investigative efforts and the development of new technologies and chemical matter are essential to fulfill the significant potential of this innovative approach to cancer treatment.
非编码RNA，尤其是微小RNA（miRNA），在癌症的发生和转移中起着关键作用，这突出了它们对通过小分子抑制剂进行精确调控的敏感性。本综述探讨了用类药物小分子靶向致癌miRNA的创新策略，这种方法能够重塑癌症治疗格局。我们回顾了目前对miRNA在肿瘤发生中多方面作用的理解，强调了有可能拓展癌症治疗选择的新兴治疗模式。由于对miRNA小分子抑制剂的研究仍处于早期阶段，持续的研究工作以及新技术和化学物质的开发对于实现这种创新癌症治疗方法的巨大潜力至关重要。
